Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Ventana Signs Antibody Deal

By Drug Discovery Trends Editor | May 31, 2012

Ventana Medical Systems Inc., a member of the Roche Group, has signed an exclusive license agreement with the German Cancer Research Center and University Hospital Heidelberg, Germany to commercialize a novel immunohistochemistry (IHC) primary antibody developed to detect the V600E BRAF mutation protein.

The BRAF protein plays a role in regulating cell signaling, and it has been shown to be mutated in many human cancers. The VENTANA antibody is being developed both as an in vitro diagnostic (IVD) and for research use only (RUO). These products are expected to be the first validated, commercially-available IHC antibodies capable of specifically detecting BRAF mutations. Cancer researchers are evaluating applications of V600E mutation testing in the diagnosis, prognosis, and prediction of patient response to therapy in major cancers including colorectal, thyroid, brain, and non-Hodgkin lymphoma.

Ventana is investigating the significance of BRAF V600E mutations in the prognosis and prediction of therapy response for patients with this type of cancer.

Andreas von Deimling, MD, Director of Neuropathology at the University Heidelberg and of DKFZ`s Clinical Cooperation Unit Neuropathology, says, “We are glad to find our mutation specific antibodies in the center of interest of so many clinicians and hope that this development will assist in improving diagnosis and directing therapy for cancer patients.”

Traditional IHC is not intended to differentiate between mutant and normal protein. Roche, Ventana, and Spring Bioscience are developing antibodies that can differentiate mutant and normal protein to enable pathologists to see clinically-relevant mutations within their cellular context.

Ventana is currently developing the V600E BRAF mutation-specific antibody for IVD use to detect V600E BRAF mutation protein on its VENTANA BenchMark series of automated instruments.

Date: May 30, 2012
Source: Ventana Medical Systems Inc.


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE